Non-profit generic drug company Civica Rx appoints former Amgen quality chief as new CEO

pharmafile | October 9, 2018 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Abbot, Amgen, Bayer, civica rx, generic drugs, hospitals 

Civica Rx, a new not-for-profit generic drug company aimed at reducing the price of lifesaving medicines, has appointed former Amgen Chief Quality Officer, Senior Vice President Quality, Martin Van Trieste as their Chief Executive Officer (CEO).

Having joined Civica as a member of its board of advisors in September 2017 Van Trieste took on the position of CEO in September of this year. The experienced pharma professional brings more than 35 years of experience to the role having previously worked for pharma firms Abbot Laboratories, Amgen and Bayer.

However the Temple University graduate, who was ranked in second position on the Medicine Maker Power List of Industry Influencers, has agreed not to receive compensation for his leadership position in the non-profit initiative, due to the philanthropic nature of the organisation.

“We are creating a public asset with a mission to ensure that essential generic medications are accessible and affordable,” said VanTrieste. “The fact that a third of the country’s hospitals have either expressed interest or committed to participate with Civica Rx shows a great need for this initiative. This will improve the situation for patients by bringing much needed competition to the generic drug market”

As of now, the Utah-headquartered company has identified 14 hospital-administered generic medicines which will be the focus of the organisation’s initial efforts. The company aims to either directly manufacture these medicines themselves or sub -contract the manufacture of the generic drugs to reputable contract research organisations (CROs).

Although initially Civica Rx aims to stabilise the supply of essential generic medicines administered in hospitals, the long-term goal is to reduce the price of generic drugs overall. The company’s first products are expected to reach the market by 2019. The initiative is expected to save both hospitals and patients millions of dollars each year.

Related Content

Amgen flag

AstraZeneca and Amgen asthma drug shows positive results in Phase III trial

AstraZeneca and Amgen’s new tezepelumab drug for the treatment of severe asthma has shown superiority …

Bayer’s cardiovascular drug shows impressive Phase III results

Bayer’s finerenone drug has been shown to significantly reduce cardiovascular death or other cardiovascular events …

Amgen flag

Amgen stomach cancer drug awarded Breakthrough Therapy Designation

Amgen’s investigational therapy, bemarituzumab, for certain types of stomach and esophagus cancer, has been granted …

Latest content